This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McAleese, F. Articles by Bradford, P. A. Search for Related Content PubMed PubMed Citation Articles by McAleese, F. Articles by Bradford, P. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2005, p. 4521-4529, Vol. 49, No. 11
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.11.4521-4529.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Use of Ribotyping To Retrospectively Identify Methicillin-Resistant Staphylococcus aureus Isolates from Phase 3 Clinical Trials for Tigecycline That Are Genotypically Related to Community-Associated Isolates

Fionnuala McAleese,¹ Ellen Murphy,¹ Timothy Babinchak,³ Guy Singh,¹ Battouli Said-Salim,⁴ Barry Kreiswirth,⁴ Paul Dunman,^1, John O'Connell,¹ Steven J. Projan,² and Patricia A. Bradford^1*

Wyeth Research, Pearl River, New York,¹ Wyeth Research, Cambridge, Massachusetts,² Wyeth Research, Collegeville, Pennsylvania,³ Public Health Research Institute, Newark, New Jersey⁴

Received 15 June 2005/ Returned for modification 24 July 2005/ Accepted 18 August 2005

A retrospective study was performed to identify methicillin-resistant Staphylococcus aureus (MRSA) isolates obtained from patients enrolled in phase 3 clinical trials for tigecycline that were genotypically similar to known community-associated MRSA (CA-MRSA) strains. The clinical trials were double-blind comparator studies for complicated skin and skin structure infections or complicated intra-abdominal infections. We obtained 85% of the MRSA isolates from patients with complicated skin and skin structure infections. Using ribotyping, MRSA isolates were compared with well-characterized North American CA-MRSA strains and negative-control hospital-associated (HA) MRSA strains by cluster analysis; 91 of the 173 isolates clustered with two groups of known CA-MRSA strains, 60% of which shared an indistinguishable ribotype. These isolates were subsequently tested for the presence of SCCmec type IV and the Panton-Valentine leukocidin (PVL)-encoding genes as well as susceptibility to clindamycin, characteristics that are typically associated with CA-MRSA; 89 of the 91 isolates carried the type IV SCCmec element and 76 were also positive for the PVL-encoding genes; 73 of these isolates were susceptible to clindamycin. A similar analysis performed on 26 nonclustering isolates identified only four with these characteristics; 89 of the 91 clustering isolates were inhibited by tigecycline at MICs of 0.5 µg/ml. On the basis of clustering information and preliminary genetic characterization, it appears that ribotyping is a useful tool in identifying potential CA-MRSA isolates and 76 MRSA isolates from patients enrolled in the tigecycline phase 3 trials have genetic markers typically associated with CA-MRSA.

Present address: Department of Microbiology and Pathology, University of Nebraska Medical Center, Omaha, NE 68198.

This article has been cited by other articles:

• Takano, T., Higuchi, W., Otsuka, T., Baranovich, T., Enany, S., Saito, K., Isobe, H., Dohmae, S., Ozaki, K., Takano, M., Iwao, Y., Shibuya, M., Okubo, T., Yabe, S., Shi, D., Reva, I., Teng, L.-J., Yamamoto, T. (2008). Novel Characteristics of Community-Acquired Methicillin-Resistant Staphylococcus aureus Strains Belonging to Multilocus Sequence Type 59 in Taiwan. Antimicrob. Agents Chemother. 52: 837-845 [Abstract] [Full Text]  
• Jones, C. H., Tuckman, M., Howe, A. Y. M., Orlowski, M., Mullen, S., Chan, K., Bradford, P. A. (2006). Diagnostic PCR Analysis of the Occurrence of Methicillin and Tetracycline Resistance Genes among Staphylococcus aureus Isolates from Phase 3 Clinical Trials of Tigecycline for Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 50: 505-510 [Abstract] [Full Text]